Can talimogene laherparepvec (T‑vec) cause syncope and hypotension?

Can T-VEC Cause Syncope and Hypotension?

Yes, talimogene laherparepvec (T-VEC) can cause syncope (fainting), though it is an uncommon adverse event that has been documented in post-marketing surveillance data.

Evidence from FDA Drug Label and Pharmacovigilance Data

The FDA-approved prescribing information for T-VEC does not list syncope or hypotension as common adverse events in the primary safety profile 1. However, a comprehensive real-world pharmacovigilance study analyzing the FDA Adverse Event Reporting System (FAERS) database from 2004-2023 identified syncope as an unexpected significant adverse event signal in T-VEC-treated patients 2. This represents a safety signal that was not prominently featured in the original prescribing information but emerged from post-marketing surveillance.

Clinical Context and Mechanism

The most common adverse effects of T-VEC are:

• Pyrexia (fever) - reported in approximately 20% of patients 3
• Chills - affecting approximately 22% of patients 3
• Influenza-like illness - occurring in approximately 15% of patients 3
• Fatigue and nausea 1

Why Syncope May Occur

The mechanism by which T-VEC could precipitate syncope likely relates to:

1. Systemic inflammatory response: The oncolytic viral therapy triggers immune activation and cytokine release, which can cause fever, chills, and flu-like symptoms 1. These systemic responses can lead to vasodilation and relative hypovolemia.

2. Vasovagal response: The combination of fever, dehydration from flu-like symptoms, and the stress of treatment could trigger reflex syncope (vasovagal syncope), which is characterized by sudden vasodilation and/or bradycardia leading to cerebral hypoperfusion 4.

3. Orthostatic intolerance: Patients experiencing significant flu-like symptoms, fever, and potential volume depletion may develop orthostatic hypotension, particularly if they have other risk factors 4.

Clinical Management Recommendations

If a patient on T-VEC experiences syncope or presyncope:

1. Immediate assessment should focus on:

   • Vital signs including orthostatic blood pressure measurements (lying and standing within 3 minutes) 4
   • ECG to exclude cardiac arrhythmia 5
   • Assessment for signs of sepsis or disseminated herpes infection (fever, altered mental status, focal neurological signs) 1, 2

2. Risk stratification: Syncope in the context of T-VEC treatment requires evaluation for:

   • Serious infection: Sepsis and encephalitis were also identified as unexpected adverse events in pharmacovigilance data 2. If syncope occurs with fever, confusion, or neurological symptoms, urgent evaluation for HSV dissemination or bacterial sepsis is mandatory 1
   • Cardiac causes: Though less likely directly related to T-VEC, structural heart disease or arrhythmia must be excluded 5
   • Reflex/orthostatic causes: Most likely mechanism given the systemic inflammatory response

3. Preventive measures for patients receiving T-VEC:

   • Adequate hydration before and after treatments
   • Avoid prolonged standing, especially during peak flu-like symptoms (first 24-48 hours post-injection)
   • Monitor for fever and treat symptomatically
   • Educate patients about warning signs of presyncope (lightheadedness, visual changes, nausea) and instruct them to sit or lie down immediately 4

Important Caveats

• Syncope is not listed among the most common adverse events in the FDA label, occurring in less than the typical reporting threshold for common side effects 1
• The pharmacovigilance signal does not establish causation but indicates a need for clinical awareness 2
• Distinguish from serious complications: Any syncope accompanied by confusion, focal neurological deficits, severe headache, or eye symptoms requires urgent evaluation for HSV encephalitis or disseminated infection 1
• Report to manufacturer: The FDA label instructs healthcare providers to call Amgen at 1-855-IMLYGIC (1-855-465-9442) for any concerning new symptoms 1

Bottom line: While syncope is an uncommon adverse event with T-VEC, it has been documented in post-marketing surveillance and likely relates to the systemic inflammatory response causing vasovagal or orthostatic mechanisms. Clinicians should maintain awareness of this possibility, ensure adequate hydration, and promptly evaluate any syncope to exclude serious infectious complications.